PRSS contributes to cetuximab resistance in colorectal cancer.

摘要: Cetuximab improves the survival of patients with metastatic colorectal cancer. The main limitation is primary and secondary resistance, underlying mechanism which requires extensive investigation. We proved that PRSS expression levels are significantly negatively associated sensitivity cancer cells to cetuximab. Detailed mechanistic analysis indicated can cleave cetuximab, leading resistance. or bevacizumab combined SPINK1, a inhibitor, inhibited cell growth more efficiently than cetuximab alone in xenograft models. serum 156 mCRC were analyzed, poor efficacy therapy was observed aberrant expression. monoclonal antibody (mAb)-treated from Cancer Genome Atlas database also evaluated determine whether higher have reduced progression-free survival. Our work provides strong scientific rationale for targeting combination therapy.